Patricia Roxburgh

1.7k total citations
50 papers, 754 citations indexed

About

Patricia Roxburgh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Patricia Roxburgh has authored 50 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Genetics. Recurrent topics in Patricia Roxburgh's work include PARP inhibition in cancer therapy (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Ovarian cancer diagnosis and treatment (10 papers). Patricia Roxburgh is often cited by papers focused on PARP inhibition in cancer therapy (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Ovarian cancer diagnosis and treatment (10 papers). Patricia Roxburgh collaborates with scholars based in United Kingdom, United States and Spain. Patricia Roxburgh's co-authors include T.R. Jeffry Evans, Michelle Ferguson, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Karen H. Vousden, Susana Banerjee, Andreas Hock, Martijn P. Lolkema, Matt Coffey and K.L. Mettinger and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patricia Roxburgh

47 papers receiving 733 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patricia Roxburgh United Kingdom 14 491 296 191 178 123 50 754
Martina Breidenbach Germany 18 316 0.6× 338 1.1× 289 1.5× 146 0.8× 166 1.3× 35 914
Deanna M. Janzen United States 12 257 0.5× 520 1.8× 108 0.6× 147 0.8× 131 1.1× 21 863
AJ Robert McGray United States 16 630 1.3× 235 0.8× 180 0.9× 47 0.3× 501 4.1× 30 945
Heidi Giordano United States 16 694 1.4× 522 1.8× 215 1.1× 249 1.4× 167 1.4× 42 1.1k
Constantia Pantelidou United States 6 528 1.1× 469 1.6× 95 0.5× 43 0.2× 275 2.2× 9 812
Elsa M. Cora United States 9 261 0.5× 330 1.1× 143 0.7× 54 0.3× 41 0.3× 15 599
Shannon Barker United States 15 431 0.9× 554 1.9× 597 3.1× 60 0.3× 76 0.6× 20 849
Naotake Tsuda Japan 21 526 1.1× 621 2.1× 115 0.6× 68 0.4× 577 4.7× 66 1.3k
Kouichiro Kawano Japan 17 292 0.6× 337 1.1× 47 0.2× 80 0.4× 391 3.2× 46 798
Nirmala Jagadish India 19 171 0.3× 622 2.1× 67 0.4× 111 0.6× 299 2.4× 35 839

Countries citing papers authored by Patricia Roxburgh

Since Specialization
Citations

This map shows the geographic impact of Patricia Roxburgh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Roxburgh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Roxburgh more than expected).

Fields of papers citing papers by Patricia Roxburgh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Roxburgh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Roxburgh. The network helps show where Patricia Roxburgh may publish in the future.

Co-authorship network of co-authors of Patricia Roxburgh

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Roxburgh. A scholar is included among the top collaborators of Patricia Roxburgh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Roxburgh. Patricia Roxburgh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Domingo, Enric, Juan Fernández‐Tajes, Kathryn A.F. Pennel, et al.. (2025). Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis. Molecular Cancer Research. 23(4). 300–312. 1 indexed citations
3.
Hollis, Robert L., Richard Elliott, John C. Dawson, et al.. (2024). High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecologic Oncology. 186. 42–52. 5 indexed citations
4.
Förster, Martin, Irene Braña, Antonio López–Pousa, et al.. (2024). Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 30(17). 3726–3734. 8 indexed citations
5.
Bell, Sarah, et al.. (2024). An overview of the molecular pathology of ovarian carcinomas. Diagnostic histopathology. 30(9). 477–486. 1 indexed citations
6.
Middleton, Gary, Lynley V. Marshall, Lucinda Billingham, et al.. (2023). 716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers. Annals of Oncology. 34. S494–S495. 1 indexed citations
7.
Roxburgh, Patricia, Douglas Cartwright, Alistair S. McLaren, et al.. (2023). Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting. Journal of Clinical Medicine. 12(7). 2497–2497. 3 indexed citations
8.
Jones, Robert H., Ruth Plummer, Víctor Moreno, et al.. (2022). A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research. 29(2). 331–340. 27 indexed citations
9.
Krebs, Matthew, M. Majem Tarruella, Martin Förster, et al.. (2022). 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Annals of Oncology. 33. S33–S33. 2 indexed citations
10.
McLaren, Alistair S., Douglas Cartwright, Ewen Ross, & Patricia Roxburgh. (2021). First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis. SHILAP Revista de lepidopterología. 4(3). 171–174. 4 indexed citations
11.
Spiliopoulou, Pavlina, Samantha Hinsley, Iain A. McNeish, Patricia Roxburgh, & Rosalind Glasspool. (2021). Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer. 31(7). 1037–1044. 11 indexed citations
12.
Moreno, Víctor, Maria-Pilar Barretina-Ginesta, Jesús García-Donás, et al.. (2021). Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer. 9(12). e003645–e003645. 35 indexed citations
13.
Någård, Mats, Mei-Lin Ah-See, Karen So, et al.. (2020). Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 86(1). 97–108. 8 indexed citations
14.
15.
16.
Wilson, Richard H., Mark R. Middleton, L. Rhoda Molife, et al.. (2017). A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer. 116(7). 884–892. 60 indexed citations
17.
Roxburgh, Patricia, L Rhoda Molife, Anubha Gupta, et al.. (2013). A phase 1 study of oral rucaparib in combination with carboplatin. European Journal of Cancer. 49. 2 indexed citations
18.
Lindsay, Colin R., Patricia Roxburgh, & Janet Graham. (2013). How Do We Optimally use Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer?. Future Oncology. 9(6). 825–829. 2 indexed citations
19.
Tan, David S.P., Timothy A. Yap, Margaret Hutka, et al.. (2012). Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer. 49(6). 1246–1253. 23 indexed citations
20.
Roxburgh, Patricia, et al.. (2012). Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis. 33(4). 791–798. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Breidenbach Breakdown of academic impact, for papers by Deanna M. Janzen Breakdown of academic impact, for papers by AJ Robert McGray Breakdown of academic impact, for papers by Heidi Giordano Breakdown of academic impact, for papers by Constantia Pantelidou Breakdown of academic impact, for papers by Elsa M. Cora Breakdown of academic impact, for papers by Shannon Barker Breakdown of academic impact, for papers by Naotake Tsuda Breakdown of academic impact, for papers by Kouichiro Kawano Breakdown of academic impact, for papers by Nirmala Jagadish
Rankless by CCL
2026